Karyopharm Therapeutics Stock Current Liabilities
| KPTI Stock | USD 0.70 0.10 16.67% |
Karyopharm Therapeutics fundamentals help investors to digest information that contributes to Karyopharm Therapeutics' financial success or failures. It also enables traders to predict the movement of Karyopharm Stock. The fundamental analysis module provides a way to measure Karyopharm Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Karyopharm Therapeutics stock.
As of now, Karyopharm Therapeutics' Total Current Liabilities is increasing as compared to previous years. The Karyopharm Therapeutics' current Non Current Liabilities Total is estimated to increase to about 322.5 M, while Non Current Liabilities Other is projected to decrease to under 929.1 K. Karyopharm | Current Liabilities |
Karyopharm Therapeutics Company Current Liabilities Analysis
Karyopharm Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Karyopharm Therapeutics Current Liabilities | 14.95 M |
Most of Karyopharm Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karyopharm Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Karyopharm Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Karyopharm Therapeutics is extremely important. It helps to project a fair market value of Karyopharm Stock properly, considering its historical fundamentals such as Current Liabilities. Since Karyopharm Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Karyopharm Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Karyopharm Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Karyopharm Current Liabilities Historical Pattern
Today, most investors in Karyopharm Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Karyopharm Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Karyopharm Therapeutics current liabilities as a starting point in their analysis.
Karyopharm Therapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Karyopharm Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Karyopharm Therapeutics has a Current Liabilities of 14.95 M. This is 99.15% lower than that of the Biotechnology sector and 97.25% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.81% higher than that of the company.
Karyopharm Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karyopharm Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics of similar companies.Karyopharm Therapeutics is currently under evaluation in current liabilities category among its peers.
Karyopharm Fundamentals
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.68) % | ||||
| Current Valuation | 149.19 M | ||||
| Shares Outstanding | 126.19 M | ||||
| Shares Owned By Insiders | 6.21 % | ||||
| Shares Owned By Institutions | 48.20 % | ||||
| Number Of Shares Shorted | 19.79 M | ||||
| Price To Earning | (3.90) X | ||||
| Price To Book | 12.05 X | ||||
| Price To Sales | 0.60 X | ||||
| Revenue | 146.03 M | ||||
| Gross Profit | 151.86 M | ||||
| EBITDA | (118.42 M) | ||||
| Net Income | (143.1 M) | ||||
| Cash And Equivalents | 170.85 M | ||||
| Cash Per Share | 2.14 X | ||||
| Total Debt | 177.02 M | ||||
| Debt To Equity | 2.59 % | ||||
| Current Ratio | 3.88 X | ||||
| Book Value Per Share | (1.27) X | ||||
| Cash Flow From Operations | (92.72 M) | ||||
| Short Ratio | 24.61 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 325 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 88.46 M | ||||
| Total Asset | 240.44 M | ||||
| Retained Earnings | (1.49 B) | ||||
| Working Capital | 164.44 M | ||||
| Current Asset | 130.25 M | ||||
| Current Liabilities | 14.95 M | ||||
| Net Asset | 240.44 M |
About Karyopharm Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Karyopharm Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Karyopharm Therapeutics Piotroski F Score and Karyopharm Therapeutics Altman Z Score analysis. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.